Why are digoxin and Lasix used together

• Patients and Caregivers
• Clinician Explanation

Monitor CloselyPotential for interaction

digoxin oral increases and furosemide oral decreases potassium levels in the blood.

Patient Drug Interactions Source: RxList

© 2022 RxList, Inc.

Monitor CloselyUse Caution/Monitor.

digoxin oral increases and furosemide oral decreases serum potassium.

Clinical Drug Interactions Source: Medscape from WebMD

© 1994-2022 WebMD, LLC.

Check for more interactions with the Drug Interaction Checker

Never use this combination of drugs because of high risk for dangerous interaction

Potential for serious interaction; regular monitoring by your doctor required or alternate medication may be needed

Potential for significant interaction (monitoring by your doctor is likely required)

Interaction is unlikely, minor, or nonsignificant

Disclaimer: The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for informational purposes only. This tool may not cover all possible drug interactions. Please check with a physician if you have health questions or concerns. Although we attempt to provide accurate and up-to-date information, no guarantee is made to that effect.

Selected from data included with permission and copyrighted by First Databank, Inc. This copyrighted material has been downloaded from a licensed data provider and is not for distribution, except as may be authorized by the applicable terms of use.

CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.

Skip to: full site navigation

Lowers blood pressure. Removes extra water from your body.

Lasix (Furosemide) is a very effective water pill and it'll certainly make you go to the bathroom more often.

3.7/ 5 average rating with 371 reviewsforLasix

Improves heart pumping.

Lanoxin (digoxin) is effective at treating heart failure symptoms, but it doesn't lower your risk of death compared to other heart failure medicines.

3.3/ 5 average rating with 70 reviewsfordigoxin

• A strong diuretic (water pill) that works well to get rid of extra fluids in your body through urination.
• Lowers your blood pressure and your risk of heart attack and stroke.
• Works better than thiazide diuretics (like Hydrochlorothiazide) at removing harmful levels of certain electrolytes, such as potassium.
• Okay to take if you have kidney problems.

• Lanoxin (digoxin) is used for abnormal heart rhythms, and for heart failure that can't be controlled by other medications.
• Lanoxin (digoxin) does not need dose adjustments with people with liver problems.
• Lanoxin (digoxin) is available in a generic form.
• Lanoxin (digoxin) can be taken once daily.

• Makes you urinate very frequently.
• Can cause low levels of important electrolytes, such as potassium.

• Lanoxin (digoxin) relieves heart failure symptoms, but doesn't lower your risk of death. It's usually used together with other medicines that help lower the risk of death in heart failure.
• Use of Lanoxin (digoxin) requires blood tests, especially during the first few weeks of treatment to monitor drug level in the body.
• If your blood levels of Lanoxin (digoxin) are too high, it can be life threatening.
• Lanoxin (digoxin) is usually not an option for people with kidney problems.

Want to save even more money?

Sign up now for a 30-day trial and save up to 95% at CVS, Kroger, Albertsons, and other pharmacies.

The Lasix (Furosemide) FDA package insert doesn’t have numbers about how common side effects are.

See more detailed side effects

• Dehydration and electrolyte imbalance

  • Current electrolyte imbalance

• Severe allergic reactions

  • History of sulfa allergies
• • Current kidney problems
  • Dose too high
  • Low blood protein
  • Other medicines that causes hearing problems

See more detailed risks and warnings

• • History of heart problems
  • Drug interactions
  • Wolff-Parkinson-White syndrome
• • Low body weight
  • Elderly (>65 years old)
  • Worsening kidney function
  • Electrolyte imbalances
• • Overactive or underactive thyroid

See more detailed risks and warnings

Learn more about Lasix (Furosemide)

Learn more about Lanoxin (digoxin)

1. Janchawee B, Wongpoowarak W, Owatranporn T, Chongsuvivatwong V. Pharmacoepidemiologic study of potential drug interactions in outpatients of a university hospital in Thailand. J Clin Pharm Ther. 2005;30:13–20. [PubMed] [Google Scholar]

2. Magro L, Conforti A, Del Zotti F, Leone R, Iorio ML, Meneghelli I, Massignani D, Visonà E, Moretti U. Identification of severe potential drug-drug interactions using an Italian general-practitioner database. Eur J Clin Pharmacol. 2008;64:303–9. [PubMed] [Google Scholar]

3. Bennett S. Diuretics: use, actions and prescribing rationale. Nurse Prescribing. 2008;6:72–7. [Google Scholar]

4. Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG, Konstam MA, Mancini DM, Rahko PS, Silver MA, Stevenson LW, Yancy CW. 2009 Focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119:1977–2016. [PubMed] [Google Scholar]

5. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Strömberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Eur J Heart Fail. 2008;10:933–89. [PubMed] [Google Scholar]

6. Hirsch AT, Dzau VJ, Creager MA. Baroreceptor function in congestive heart failure: effect on neurohumoral activation: effect on neurohumoral activation and regional vascular resistance. Circulation. 1987;75:IV36–48. [PubMed] [Google Scholar]

7. Gheorghiade M, Ferguson D. Digoxin. A neurohormonal modulator in heart failure? Circulation. 1991;84:2171–86. [PubMed] [Google Scholar]

8. Pervaiz MH, Dickinson MG, Yamani M. Is digoxin a drug of the past? Cleve Clin J Med. 2006;73:821–34. [PubMed] [Google Scholar]

9. The Digitalis Investigation Group. The effects of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336:523–33. [PubMed] [Google Scholar]

10. Hood WB, Jr, Dans AL, Guyatt GH, Jaeschke R, McMurray JJ. Digitalis for treatment of congestive heart failure in patients in sinus rhythm: a systematic review and meta-analysis. J Card Fail. 2004;10:155–64. [PubMed] [Google Scholar]

11. Moser M. Do diuretics differ in terms of clinical outcome in congestive heart failure? Cardiovasc Drugs Ther. 1997;11(Suppl):273–7. [PubMed] [Google Scholar]

12. Allen LA, O’Connor CM. Management of acute decompensated heart failure. CMAJ. 2007;176:797–805. [PMC free article] [PubMed] [Google Scholar]

13. Follath F. Do diuretics differ in terms of clinical outcome in congestive heart failure? Eur Heart J. 1998;19:5–8. Suppl. [PubMed] [Google Scholar]

14. Howlett JG. Current treatment options for early management in acute decompensated heart failure. Can J Cardiol. 2008;24:9B–13B. [PMC free article] [PubMed] [Google Scholar]

15. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709–17. [PubMed] [Google Scholar]

16. Tatro DS, editor. Drug Interaction Facts™ 2007. The Authority on Drug Interactions. St. Louis, MO: Wolters Kluwer Health; 2007. [Google Scholar]

17. Morgan DB, Davidson C. Hypokalaemia and diuretics: an analysis of publications. Br Med J. 1980;280:905–08. [PMC free article] [PubMed] [Google Scholar]

18. Eichhorn EJ, Gheorghiade M. Digoxin. Prog Cardiovasc Dis. 2002;44:251–66. [PubMed] [Google Scholar]

19. Wilkerson RD. Acute effects of intravenous furosemide administration on serum digoxin concentration. Am Heart J. 1981;102:63–5. [PubMed] [Google Scholar]

20. Steiness E, Olesen KH. Cardiac arrhythmias induced by hypokalaemia and potassium loss during maintenance digoxin therapy. Br Heart J. 1976;38:167–72. [PMC free article] [PubMed] [Google Scholar]

21. Lim P, Jacob E. Magnesium deficiency in patients on long-term diuretic therapy for heart failure. Br Med J. 1972;3:620–2. [PMC free article] [PubMed] [Google Scholar]

22. Whang R, Oei TO, Watanabe A. Frequency of hypomagnesemia in hospitalized patients receiving digitalis. Arch Intern Med. 1985;145:655–6. [PubMed] [Google Scholar]

23. Hsiao FY, Yang CL, Huang YT, Huang WF. Using Taiwan's national health insurance research databases for pharmacoepidemiology research. J Food Drug Anal. 2007;15:99–108. [Google Scholar]

24. Yang SY, Kao YH, Chong MY, Yang YH, Chang WH, Lai CS. Risk of extrapyramidal syndrome in schizophrenic patients treated with antipsychotics: a population-based study. Clin Pharmacol Ther. 2007;81:586–94. [PubMed] [Google Scholar]

25. Chen CY, Chiu HF, Yeh MK, Chang CC, Yang CY. The use of anti-asthmatic medications among pediatric patients in Taiwan. Pharmacoepidemiol Drug Saf. 2003;12:129–33. [PubMed] [Google Scholar]

26. McCullough PA, Philbin EF, Spertus JA, Kaatz S, Sandberg KR, Weaver WD Resource Utilization Among Congestive Heart Failure (REACH) Study. Confirmation of a heart failure epidemic: findings from the Resource Utilization Among Congestive Heart Failure (REACH) study. J Am Coll Cardiol. 2002;39:60–9. [PubMed] [Google Scholar]

27. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83. [PubMed] [Google Scholar]

28. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613–9. [PubMed] [Google Scholar]

29. De Bruin ML, van Hemel NM, Leufkens HG, Hoes AW. Hospital discharge diagnoses of ventricular arrhythmias and cardiac arrest were useful for epidemiologic research. J Clin Epidemiol. 2005;58:1325–9. [PubMed] [Google Scholar]

30. Lakshminarayan K, Solid CA, Collins AJ, Anderson DC, Herzog CA. Atrial fibrillation and stroke in the general medicare population: a 10-year perspective (1992 to 2002) Stroke. 2006;37:1969–74. [PubMed] [Google Scholar]

31. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, Saunders LD, Beck CA, Feasby TE, Ghali WA. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43:1130–9. [PubMed] [Google Scholar]

32. Goettsch WG, Heintjes EM, Kastelein JJ, Rabelink TJ, Johansson S, Herings RM. Results from a rosuvastatin historical cohort study in more than 45,000 Dutch statin users, a PHARMO study. Pharmacoepidemiol Drug Saf. 2006;15:435–43. [PubMed] [Google Scholar]

33. Gennari FJ. Hypokalemia. N Engl J Med. 1998;339:451–8. [PubMed] [Google Scholar]

34. Greenland S. Modeling and variable selection in epidemiologic analysis. Am J Public Health. 1989;79:340–9. [PMC free article] [PubMed] [Google Scholar]

35. Chan ALF, Wang MT, Su CY, Tsai FH. Risk of digoxin intoxication caused by clarithromycin-digoxin interactions in heart failure patients: a population-based study. Eur J Clin Pharmacol. 2009;65:1237–43. [PubMed] [Google Scholar]

36. Ward RE, Gheorghiade M, Young JB, Uretsky B. Economic outcomes of withdrawal of digoxin therapy in adult patients with stable congestive heart failure. J Am Coll Cardiol. 1995;26:93–101. [PubMed] [Google Scholar]

37. Lehmann HU, Witt E, Temmen L, Hochrein H. Life-threatening digitalis intoxication with and without additional diuretic treatment. Dtsch Med Wochenschr. 1978;103:1566–71. [PubMed] [Google Scholar]

38. Kjeldsen K, Norgaard A, Gheorghiade M. Myocardial Na,K-ATPase: the molecular basis for the hemodynamic effect of digoxin therapy in congestive heart failure. Cardiovasc Res. 2002;55:710–3. [PubMed] [Google Scholar]

39. Katzung BG, Parmley WW. Drugs used in heart failure. In: Katzung BG, editor. Basic & Clinical Pharmacology. Ninth. New York: McGraw Hill; 2004. pp. 201–15. edn, ed. [Google Scholar]

40. Brater DC, Morrelli HF. Digoxin toxicity in patients with normokalemic potassium depletion. Clin Pharmacol Ther. 1977;22:21–33. [PubMed] [Google Scholar]

41. Steiness E. Digoxin toxicity compared with myocardial digoxin and potassium concentration. Br J Pharmacol. 1978;63:233–7. [PMC free article] [PubMed] [Google Scholar]

42. Hanratty CG, McGlinchey P, Johnston GD, Passmore AP. Differential pharmacokinetics of digoxin in elderly patients. Drug Aging. 2000;17:353–62. [PubMed] [Google Scholar]

43. Waldorff S, Hansen PB, Egeblad H, Berning J, Buch J, Kjaergård H, Steiness E. Interactions between digoxin and potassium–sparing diuretics. Clin Pharmacol Ther. 1983;33:418–23. [PubMed] [Google Scholar]

44. Juurlink DN, Mamdani M, Kopp A, Laupacis A, Redelmeier DA. Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA. 2003;289:1652–8. [PubMed] [Google Scholar]

45. Juurlink DN, Mamdani MM, Kopp A, Herrmann N, Laupacis A. A population-based assessment of the potential interaction between serotonin-specific reuptake inhibitors and digoxin. Br J Clin Pharmacol. 2005;59:102–7. [PMC free article] [PubMed] [Google Scholar]

Page 2

Characteristics of cases and matched controls